The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands

References

• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Iqbal MB, Taneja AK, Lip GY, et al. Recent developments in atrial fibrillation. BMJ 2005;330:238-43
   PubMed Web of Science ®Google Scholar
• Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53
   PubMed Web of Science ®Google Scholar
• van der Linden MWW, de Bakker GP, Schellevis DH, et al. Nationale studie naar ziekten en verrichtingen in de huisartspraktijk. Klachten en aandoeningen in de bevolking en in de huisartspraktijk. [Second national study on illnesses in the general practice] Utrecht/Bilthoven: NIVEL; 2004
   Google Scholar
• Opstelten W, Boode BS, Heeringa J, et al. [Summary of the practice guideline 'Atrial fibrillation' (first revision) from the Dutch College of General Practitioners]. Nederlands tijdschrift voor geneeskunde 2010;154:A1570
   PubMedGoogle Scholar
• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746-51
   PubMed Web of Science ®Google Scholar
• National Institute of Public Health and Enviroment. Volksgezondheid.info: Ranglijst ziekten op basis van ziektelast (in DALY’s) [Public health and health care: ranking diseases on disease burden (in DALY’s)] [Internet]. 2017. https://www.volksgezondheidenzorg.info/ranglijst/ranglijst-ziekten-op-basis-van-ziektelast-dalys
   Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2Suppl):e531S-75S
   Web of Science ®Google Scholar
• Anonymous. Cost of stroke in The Netherlands (2011). National Institute for Public Health and the Environment; 2016. Available at: https://kostenvanziektentool.volksgezondheidenzorg.info/tool/nederlands/?ref=kvz_v2l1b1p4r4c2i0t1j0o3y6a-1g0d50s54z0f0w2
   Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
   PubMed Web of Science ®Google Scholar
• Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6
   PubMed Web of Science ®Google Scholar
• Virjo I, Makela K, Aho J, et al. Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. Scand J Primary Health Care 2010;28:237-41
   PubMed Web of Science ®Google Scholar
• Korenstra J, Wijtvliet EP, Veeger NJ, et al. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. Europace 2016;18:1319-27
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Zheng I, Sorensen SV, Gonschior AK, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther 2014;36:2015-28.e2
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriat Soc 2006;54:1231-6
   PubMed Web of Science ®Google Scholar
• Statistics Netherlands 2016. Available at: http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37360ned&D1=0,3&D2=a&D3=a&D4=94&HDR=G1,T&STB=G2,G3&VW=T
   Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making Int J Soc Med Decis Making 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32:1425-9
   PubMed Web of Science ®Google Scholar
• The National Health Care Institute. Guidelines for the conduction of economic evaluations in health care. Diemen: The National Health Care Institute; 2016
   Google Scholar
• van den Berg B, Brouwer W, van Exel J, et al. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med 2006;62:835-45
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83
   PubMed Web of Science ®Google Scholar
• Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333
   PubMed Web of Science ®Google Scholar
• Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ 2013;16:407-14
   PubMedGoogle Scholar
• Krejczy M, Harenberg J, Marx S, et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis 2014;37:507-23
   PubMed Web of Science ®Google Scholar
• Davidson T, Husberg M, Janzon M, et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J 2013;34:177-83
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017;377:431-441
   PubMed Web of Science ®Google Scholar
• Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001;6:92-8
   PubMedGoogle Scholar
• The National Health Care Institute. Consumer reimbursement price. 2017. Available at: http://medicijnkosten.nl/
   Google Scholar
• Netherlands HCot. New anticoagulants: a well-dosed introduction. Vol. publication no. 2012/07. The Hague: Health Council of the Netherlands; 2012
   Google Scholar
• Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg [Manual for costing studies: methodes and standard prices]. Diemen: Health Care insurance board; 2010
   Google Scholar
• van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001;22:751-61
   PubMed Web of Science ®Google Scholar
• Baeten SA, van Exel NJ, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Effect Resour Alloc C/E 2010;8:21
   PubMedGoogle Scholar
• Groot M. Cost-effectiveness of melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery. Economic Evaluation Serving different actors in a changing environment; some examples [Thesis]. Rotterdam; 2006
   Google Scholar
• The Dutch Health Care Authority. The Hague: DRG tariffs; 2014. http://dbc-zorgproducten-tarieven.nza.nl/nzaZpTarief/ZoekfunctieDbc.aspx
   Google Scholar
• Vonkeman HE, Klok RM, Postma MJ, et al. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging 2007;24:681-90
   PubMed Web of Science ®Google Scholar
• Soekhlal RR, Burgers LT, Redekop WK, et al. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J. 2013;21:230-5
   PubMed Web of Science ®Google Scholar